Cancer is detected through a combination of recognizing early warning signs, following routine screening schedules, and undergoing diagnostic tests like imaging and biopsies when something suspicious appears. No single test catches every type of cancer, so detection relies on multiple layers: your own awareness of changes in your body, age-appropriate screenings, and the diagnostic tools your doctor uses to investigate further.
Warning Signs Worth Knowing
Many cancers produce noticeable symptoms long before a diagnosis, but the challenge is that these symptoms often mimic common, harmless conditions. A helpful framework groups the key warning signs under the acronym CAUTION:
- Changes in bowel or bladder habits: persistent diarrhea, constipation, pain during urination, or blood in your stool or urine.
- A sore that doesn’t heal: any wound or lesion that persists or grows despite appropriate treatment.
- Unusual bleeding or discharge: from any part of the body, including nipples or genitalia. Bloody nipple discharge can signal breast cancer; unexpected vaginal bleeding may point to uterine or cervical cancer.
- Thickening or lump: especially in the breast or testicles, though lumps anywhere on the body deserve attention.
- Indigestion or difficulty swallowing: persistent discomfort after eating, bloating, or trouble getting food down can indicate cancers of the mouth, throat, esophagus, or stomach.
- Obvious changes in a wart or mole: shifts in color, shape, or size may signal skin cancer.
- Unexplained weight loss: losing weight without trying, especially alongside fatigue and loss of appetite, can be a sign of advanced cancer.
None of these symptoms means you have cancer. Most of the time, the cause is something far less serious. But symptoms that persist for weeks, worsen over time, or can’t be explained by another condition are worth bringing to a doctor promptly.
The ABCDE Rule for Skin Cancer
Skin cancer has its own visual checklist. The ABCDE rule, developed by the National Cancer Institute, describes features of early melanoma you can spot yourself:
- Asymmetry: one half of the mole doesn’t match the other.
- Border: the edges are ragged, notched, or blurred rather than smooth.
- Color: the pigment is uneven, with mixed shades of black, brown, tan, or areas of white, red, pink, or blue.
- Diameter: the spot is larger than about 6 millimeters (roughly the size of a pencil eraser), or it’s growing.
- Evolving: the mole has changed in size, shape, or color over the past few weeks or months.
A mole that checks even one of these boxes is worth having a dermatologist examine. Melanoma caught early is highly treatable, while late-stage melanoma is far more dangerous.
Routine Screening Schedules
Screening tests look for cancer before you have any symptoms, which is why they’re so valuable. The U.S. Preventive Services Task Force (USPSTF) sets evidence-based guidelines for the most common screenable cancers.
Breast Cancer
Screening mammography is recommended every two years for women aged 40 to 74. If you have a strong family history or known genetic risk factors, your doctor may recommend starting earlier or screening more frequently.
Colorectal Cancer
Screening should begin at age 45 for everyone at average risk. From 50 to 75, screening carries the strongest recommendation. Options include colonoscopy, stool-based tests, and other methods, so you can choose what works best for you.
Cervical Cancer
Women aged 21 to 29 should have a Pap test every three years. From 30 to 65, you can choose between a Pap test every three years, an HPV test every five years, or a combination of both every five years.
Lung Cancer
Annual low-dose CT scans are recommended for adults aged 50 to 80 who have a 20 pack-year smoking history and either currently smoke or quit within the past 15 years. A pack-year equals smoking one pack per day for one year, so 20 pack-years could mean one pack a day for 20 years or two packs a day for 10. Screening stops once you’ve been smoke-free for 15 years.
Blood Tests and Tumor Markers
Blood tests alone rarely confirm a cancer diagnosis, but they play an important supporting role. Tumor markers are substances that certain cancers release into the bloodstream, and measuring their levels helps doctors detect cancer, track how well treatment is working, or catch a recurrence early.
The most commonly used tumor markers include PSA for prostate cancer, CA-125 for ovarian cancer, CEA for colorectal cancer, AFP for liver cancer and certain ovarian tumors, and CA19-9 for pancreatic and bile duct cancers. These markers aren’t perfectly specific. PSA, for instance, can be elevated due to a nonthreatening enlarged prostate. That’s why an abnormal marker result typically leads to further testing rather than an immediate diagnosis.
Some markers are tested on the tumor tissue itself rather than blood. Breast cancer tumors, for example, are tested for hormone receptors and a protein called HER2, which helps guide treatment decisions after diagnosis.
Imaging: CT, MRI, and PET Scans
When a doctor suspects cancer or needs to understand its extent, imaging scans provide a detailed look inside the body. Each type of scan has different strengths.
CT scans combine X-rays to create cross-sectional images and are widely used for initial cancer detection and staging. They show the size, shape, and location of tumors clearly. MRI uses magnetic fields instead of radiation and provides superior contrast for soft tissues, making it the preferred choice for brain cancers, musculoskeletal tumors, and certain abdominal cancers. PET scans highlight metabolic activity, essentially showing which cells are using the most energy. Because cancer cells tend to be highly active, they light up on PET scans, helping doctors distinguish active tumors from scar tissue or benign changes.
These scans are often combined. PET/CT is the most common pairing, giving doctors both a metabolic map and a detailed anatomical picture in one session. This combination helps determine whether a cancer has spread to other parts of the body, which is critical for staging and treatment planning. PET/MRI is newer and particularly useful for brain tumors, where it can help distinguish tumor recurrence from changes caused by prior treatment.
Biopsies: The Definitive Test
Imaging and blood tests raise suspicion, but a biopsy is what confirms a cancer diagnosis. During a biopsy, a small sample of tissue is removed and examined under a microscope by a pathologist.
The three main types differ in how much tissue they collect. Fine-needle aspiration uses a thin needle and syringe to draw out fluid and cells from a suspicious area. It’s the least invasive option, often used for lumps near the surface like thyroid nodules or enlarged lymph nodes. Core needle biopsy uses a larger needle with a cutting tip to extract a small column of tissue, providing more material for analysis. Surgical biopsy involves making an incision to access the suspicious area and may remove part or all of the abnormal tissue. Doctors typically recommend surgical biopsy when the area can’t be reached with a needle or when earlier needle biopsies came back inconclusive.
Results can come back within a few hours in urgent situations, but more commonly you’ll wait anywhere from a few days to over a week. The pathologist examines the cells, determines whether they’re cancerous, and if so, identifies the type and grade of cancer. This information shapes every treatment decision that follows.
Genetic Testing for Hereditary Risk
About 5 to 10 percent of cancers are driven by inherited gene mutations, and genetic testing can identify people who carry them. Clinical guidelines recommend testing for anyone diagnosed with triple-negative breast cancer, ovarian cancer, pancreatic cancer, colorectal cancer before age 50, metastatic prostate cancer, or male breast cancer.
Even without a personal cancer diagnosis, certain family history patterns suggest genetic testing is worthwhile. These include having a first-degree relative (parent, sibling, or child) with a known cancer-linked mutation, multiple family members with the same type of cancer, relatives with both breast and ovarian cancer or both colon and endometrial cancer, cancer diagnosed at an unusually young age, or cancer in both of a paired organ (both breasts or both kidneys). Identifying an inherited mutation doesn’t mean cancer is inevitable, but it allows for earlier and more frequent screening, preventive measures, and informed family planning.
Multi-Cancer Blood Tests
A newer category of testing, called multi-cancer early detection (MCED), aims to screen for dozens of cancer types from a single blood draw by detecting fragments of DNA that tumors shed into the bloodstream. The concept is promising because it could catch cancers that currently have no routine screening test, like pancreatic or ovarian cancer.
However, none of these tests have been approved for clinical use yet. Several are in large-scale clinical trials and seeking regulatory approval, but significant questions remain about their accuracy, false-positive rates, and whether early detection through these tests actually improves outcomes. For now, they’re not a substitute for established screening methods.